172 related articles for article (PubMed ID: 16585205)
1. Rational design of the microtubule-targeting anti-breast cancer drug EM015.
Aneja R; Lopus M; Zhou J; Vangapandu SN; Ghaleb A; Yao J; Nettles JH; Zhou B; Gupta M; Panda D; Chandra R; Joshi HC
Cancer Res; 2006 Apr; 66(7):3782-91. PubMed ID: 16585205
[TBL] [Abstract][Full Text] [Related]
2. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.
Aneja R; Vangapandu SN; Lopus M; Viswesarappa VG; Dhiman N; Verma A; Chandra R; Panda D; Joshi HC
Biochem Pharmacol; 2006 Aug; 72(4):415-26. PubMed ID: 16780803
[TBL] [Abstract][Full Text] [Related]
5. Determination of noscapine's localization and interaction with the tubulin-α/β heterodimer.
Alisaraie L; Tuszynski JA
Chem Biol Drug Des; 2011 Oct; 78(4):535-46. PubMed ID: 21781284
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
7. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
8. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
[TBL] [Abstract][Full Text] [Related]
9. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
[TBL] [Abstract][Full Text] [Related]
10. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid.
Naik PK; Chatterji BP; Vangapandu SN; Aneja R; Chandra R; Kanteveri S; Joshi HC
J Comput Aided Mol Des; 2011 May; 25(5):443-54. PubMed ID: 21544622
[TBL] [Abstract][Full Text] [Related]
11. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
12. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation.
Ghaly PE; Abou El-Magd RM; Churchill CD; Tuszynski JA; West FG
Oncotarget; 2016 Jun; 7(26):40518-40530. PubMed ID: 27777381
[TBL] [Abstract][Full Text] [Related]
13. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.
Landen JW; Lang R; McMahon SJ; Rusan NM; Yvon AM; Adams AW; Sorcinelli MD; Campbell R; Bonaccorsi P; Ansel JC; Archer DR; Wadsworth P; Armstrong CA; Joshi HC
Cancer Res; 2002 Jul; 62(14):4109-14. PubMed ID: 12124349
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel and improved antimitotic agents derived from noscapine.
Anderson JT; Ting AE; Boozer S; Brunden KR; Crumrine C; Danzig J; Dent T; Faga L; Harrington JJ; Hodnick WF; Murphy SM; Pawlowski G; Perry R; Raber A; Rundlett SE; Stricker-Krongrad A; Wang J; Bennani YL
J Med Chem; 2005 Nov; 48(23):7096-8. PubMed ID: 16279766
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and studies of small molecule STAT3 inhibitors.
Bhasin D; Cisek K; Pandharkar T; Regan N; Li C; Pandit B; Lin J; Li PK
Bioorg Med Chem Lett; 2008 Jan; 18(1):391-5. PubMed ID: 18006313
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of alpha-hydroxymethylated conjugated nitroalkenes for their anticancer activity: inhibition of cell proliferation by targeting microtubules.
Mohan R; Rastogi N; Namboothiri IN; Mobin SM; Panda D
Bioorg Med Chem; 2006 Dec; 14(23):8073-85. PubMed ID: 16891118
[TBL] [Abstract][Full Text] [Related]
17. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Landen JW; Hau V; Wang M; Davis T; Ciliax B; Wainer BH; Van Meir EG; Glass JD; Joshi HC; Archer DR
Clin Cancer Res; 2004 Aug; 10(15):5187-201. PubMed ID: 15297423
[TBL] [Abstract][Full Text] [Related]
18. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
19. Two novel series of allocolchicinoids with modified seven membered B-rings: design, synthesis, inhibition of tubulin assembly and cytotoxicity.
Büttner F; Bergemann S; Guénard D; Gust R; Seitz G; Thoret S
Bioorg Med Chem; 2005 May; 13(10):3497-511. PubMed ID: 15848763
[TBL] [Abstract][Full Text] [Related]
20. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs.
Singh VK; Zhou Y; Marsh JA; Uversky VN; Forman-Kay JD; Liu J; Jia Z
Cancer Res; 2007 Jan; 67(2):626-33. PubMed ID: 17234772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
